Results 141 to 150 of about 95,123 (282)

BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects [PDF]

, 2020
Paraskevi Apostolou, Florentia Fostira, Charalambos Kouroussis, Despoina Kalfakakou, Angeliki Delimitsou, Sofia Agelaki, Nikolaos Androulakis, Christos Christodoulou, K. Kalbakis, A. Kalykaki, Elias Sanidas, Christos Papadimitriou, Lambros Vamvakas, Vassilis Georgoulias, Dimitris Mavroudis, Drakoulis Yannoukakos, Irene Konstantopoulou, Emmanouil Saloustros   +17 more
openalex   +1 more source

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, EarlyView.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

Structure of the DNA-bound BRCA1 C-terminal Region from Human Replication Factor C p140 and Model of the Protein-DNA Complex [PDF]

, 2010
Masakazu Kobayashi, Eiso AB, Alexandre M. J. J. Bonvin, Gregg Siegal   +3 more
openalex   +1 more source

Supplementary Figure 5 from RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage

, 2023
Junko Iijima, Zhihong Zeng, Shunichi Takeda, Yoshihito Taniguchi   +3 more
openalex   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Supplementary Methods from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors

, 2023
Sven Rottenberg, Marieke A. Vollebergh, Bas de Hoon, Jorma de Ronde, Philip C. Schouten, Ariena Kersbergen, Serge A.L. Zander, Marina Pajic, Janneke E. Jaspers, Martijn Jonkers, Martin Lodén, Wendy Sol, Eline van der Burg, Jelle Wesseling, Jean‐Pierre Gillet, Michael M. Gottesman, Joost Gribnau, Lodewyk F.A. Wessels, Sabine C. Linn, Jos Jonkers, Piet Borst   +20 more
openalex   +1 more source

Targeting Genome Maintenance Defects of Cancers Using Chain‐Terminating Nucleoside Analogs

Cancer Science, EarlyView.
Nucleoside analogs interfere with DNA replication either by their chain‐terminating properties or by serving as DNA damage on the template. The genome maintenance pathways required to maintain cellular tolerance to each nucleoside analog vary depending on the drug.
Ryotaro Kawasumi, Rubaiat E. Tabassum, Kouji Hirota   +2 more
wiley   +1 more source

BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients. [PDF]

, 1997
Alex M. Garvin, M Attenhofer-Haner, Rodney J. Scott   +2 more
openalex   +1 more source

Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh, Nathalie Vermeulen, Carolyn Ee, Helena Teede, Amanda J. Vincent   +4 more
wiley   +1 more source

Identification of BCL2L11 as a Candidate Gene for Hereditary Predisposition to Non‐Medullary Thyroid Cancer Using Familial Whole‐Exome‐Sequencing

Clinical Genetics, EarlyView.
Whole‐exome sequencing of five families with non‐medullary thyroid cancer revealed three candidate genes. Functional analyses confirmed BCL2L11 as a strong candidate gene for hereditary predisposition to non‐medullary thyroid cancer. ABSTRACT Familial non‐medullary thyroid cancer, defined as two or more affected first‐degree relatives, accounts for 3 ...
Duygu Abbasoglu, Mathis Lepage, Nicolas Sonnier, Sandrine Viala, Nancy Uhrhammer, Flora Ponelle‐Chachuat, Anne Cayre, Maud Privat, Mathias Cavaillé, Yannick Bidet   +9 more
wiley   +1 more source